A team of researchers inside Pfizer made a startling find in 2015: The company’s blockbuster rheumatoid arthritis therapy Enbrel, a powerful anti-inflammatory drug, appeared to reduce the risk of Alzheimer’s disease by 64 percent.
The results were from an analysis of hundreds of thousands of insurance claims. Verifying that the drug would actually have that effect in people would require a costly clinical trial (80 millions Dollars) and after several years of internal discussion, Pfizer opted against further investigation and chose not to make the data public, the company confirmed.
“Enbrel could potentially safely prevent, treat and slow progression of Alzheimer’s disease,’’ said the document that was prepared for review by an internal Pfizer committee in February 2018.
The decision is based on patent protection which is close to an end.
The decision is based on patent protection which is close to an end.
No comments:
Post a Comment